NCT06243315View on ClinicalTrials.gov

A Prospective, Multicenter, Post-marketing Clinical Follow-up Research to Evaluate the Long-term Safety of Ellansé-S Dermal Filler Made of PCL Microspheres for the Correction of Moderate-to-severe Nasolabial Folds

Enrolling by invitationOBSERVATIONAL
Enrollment

374

Participants

Timeline

Start Date

October 12, 2023

Primary Completion Date

September 30, 2029

Study Completion Date

September 30, 2029

Conditions
Moderate-to-severe Nasolabial Folds (3-4 Level of WSRS Scores) on Both Sides of the Face
Interventions
DEVICE

Ellansé-S

It is indicated for subcutaneous implantation to correct moderate-to-severe NLFs

Trial Locations (1)

Unknown

Guangdong Second People's Hospital, Guangzhou

Sponsors

Lead Sponsor

AQTIS Medical B.V.
All Listed Sponsors
lead

AQTIS Medical B.V.

OTHER

NCT06243315 - A Prospective, Multicenter, Post-marketing Clinical Follow-up Research to Evaluate the Long-term Safety of Ellansé-S Dermal Filler Made of PCL Microspheres for the Correction of Moderate-to-severe Nasolabial Folds | Biotech Hunter | Biotech Hunter